Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
34.1M
-
Shares change
-
+461K
-
Total reported value, excl. options
-
$521M
-
Value change
-
+$394K
-
Put/Call ratio
-
0.67
-
Number of buys
-
55
-
Number of sells
-
-36
-
Price
-
$15.28
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q3 2021
145 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q3 2021.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.1M shares
of 77.3M outstanding shares and own 44.08% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (3.65M shares), FMR LLC (3.06M shares), PERCEPTIVE ADVISORS LLC (2.02M shares), BVF INC/IL (1.57M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (1.51M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.18M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.16M shares), Point72 Asset Management, L.P. (1.08M shares), Capital International Investors (1.06M shares), and NEA Management Company, LLC (992K shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.